Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2018’, provides an overview of the Influenza A Virus, H5N1 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H5N1 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H5N1 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Akshaya Bio Inc

Altimmune Inc

Antigen Express Inc

Aphios Corp

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

CEL-SCI Corp

Cocrystal Pharma Inc

Curevac AG

Hemispherx Biopharma Inc

iBio Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Medicago Inc

Microbiotix Inc

NanoViricides Inc

OPKO Health Inc

PeptiDream Inc

Shionogi & Co Ltd

TechnoVax Inc

Vaxart Inc

Vaxine Pty Ltd

VirionHealth Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Influenza A Virus, H5N1 Subtype Infections Overview 6

Influenza A Virus, H5N1 Subtype Infections Therapeutics Development 7

Influenza A Virus, H5N1 Subtype Infections Therapeutics Assessment 17

Influenza A Virus, H5N1 Subtype Infections Companies Involved in Therapeutics Development 25

Influenza A Virus, H5N1 Subtype Infections Drug Profiles 37

Influenza A Virus, H5N1 Subtype Infections Dormant Projects 125

Influenza A Virus, H5N1 Subtype Infections Discontinued Products 129

Influenza A Virus, H5N1 Subtype Infections Product Development Milestones 130

Appendix 140

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Abivax SA, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Akshaya Bio Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Altimmune Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Antigen Express Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Aphios Corp, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by AusBio Ltd, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by BiondVax Pharmaceuticals Ltd, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by BlueWillow Biologics Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by CEL-SCI Corp, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Cocrystal Pharma Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Curevac AG, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Hemispherx Biopharma Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by iBio Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Inovio Pharmaceuticals Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Johnson & Johnson, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Kineta Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Medicago Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Microbiotix Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by NanoViricides Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by OPKO Health Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by PeptiDream Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Shionogi & Co Ltd, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by TechnoVax Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Vaxart Inc, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by Vaxine Pty Ltd, H2 2018

Influenza A Virus, H5N1 Subtype Infections Pipeline by VirionHealth Ltd, H2 2018

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H2 2018

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H2 2018 (Contd..1), H2 2018

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H2 2018 (Contd..2), H2 2018

Influenza A Virus, H5N1 Subtype Infections Dormant Projects, H2 2018 (Contd..3), H2 2018

Influenza A Virus, H5N1 Subtype Infections Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports